{"ModuleTitle": "Company Description", "CompanyName": "Celsion Corporation", "Symbol": "CLSN", "Address": "997 LENOX DRIVE SUITE 100, LAWRENCEVILLE, New Jersey, 08648, United States of America", "Phone": "(609) 896-9100", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Celsion is a fully-integrated development clinical stage oncology drug company\r\nfocused on advancing innovative cancer treatments, including directed\r\nchemotherapies, DNA-mediated immunotherapy and RNA based therapies. Our lead\r\nproduct candidate is ThermoDox\u00ae, a proprietary heat-activated liposomal\r\nencapsulation of doxorubicin, currently in a Phase III clinical trial for the\r\ntreatment of primary liver cancer (the \"OPTIMA Study\"). Second in our pipeline\r\nis GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian\r\ncancer. These investigational products are based on technologies that provide\r\nthe platform for the future development of a range of therapeutics for\r\ndifficult-to-treat forms of cancer. The first technology is Lysolipid Thermally\r\nSensitive Liposomes, a heat sensitive liposomal based dosage form that targets\r\ndisease with known chemotherapeutics in the presence of mild heat.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2019%2f03%2f29%2f0001493152-19-004184.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Jeffrey Wayne Church", "title": "CFO, Secretary & SVP-Investor Relations"}, {"name": "Khursheed Anwer", "title": "Chief Scientific Officer & Executive VP"}, {"name": "Michael H. Tardugno", "title": "Chairman, President & Chief Executive Officer"}, {"name": "Nicholas Borys", "title": "Chief Medical Officer & Senior Vice President"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}